Drug intelligence / Profile preview

p110β siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Cell Transfection, Not Applicable (research Tool, No Clinical Use)
01

Overview

p110β siRNA is a synthetic or vector-based small interfering RNA (siRNA) designed to specifically induce RNA interference-mediated knockdown of the p110β catalytic subunit of PI3-kinase (phosphatidylinositol 3-kinase), encoded by the PIK3CB gene[1][2]. The mechanism of action is sequence-specific degradation of PIK3CB mRNA, leading to reduced protein levels of p110β and consequent inhibition of PI3-kinase signaling[1]. This approach is used for research purposes, especially in the elucidation of gene function and in studies of the role of p110β in cellular processes such as proliferation, migration, survival, and invasion[1]. p110β siRNA has demonstrated biological effects such as inhibition of invasive cell growth in vitro and in tumor models when compared to controls[1]. However, the effects can differ from those observed with small-molecule inhibitors of p110β due to the broader impact on protein-protein interactions and complex stability[3].

02

Targets

PIK3CB (Phosphatidylinositol 3-kinase beta subunit)

Beyond the preview

Go deeper on p110β siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on p110β siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call